Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,709 GBX | +0.20% | +2.08% | +17.82% |
Mar. 28 | GSK : Sell rating from JP Morgan | ZD |
Mar. 28 | U.S. FDA approves Akebia's anemia drug | RE |
Business Summary
Number of employees: 70,212
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Commercial Operations
100.0
%
| 29,324 | 100.0 % | 30,328 | 100.0 % | +3.42% |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
52.2
%
| 14,542 | 49.6 % | 15,820 | 52.2 % | +8.79% |
Rest of World
45.6
%
| 14,087 | 48.0 % | 13,815 | 45.6 % | -1.93% |
United Kingdom
2.3
%
| 695 | 2.4 % | 693 | 2.3 % | -0.29% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Amy Altshul
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Tech/Sci/R&D Officer | - | 17-12-31 | |
Tony Wood
CTO | Chief Tech/Sci/R&D Officer | - | 17-07-31 |
Hal Barron
BRD | Director/Board Member | 62 | 17-12-31 |
David Redfern
PRN | Corporate Officer/Principal | 57 | 93-12-31 |
Frannie DeFranco
PRN | Corporate Officer/Principal | - | 10-08-31 |
Claire Lund
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Urs Rohner
BRD | Director/Board Member | 65 | 14-12-31 |
Hal Barron
BRD | Director/Board Member | 62 | 17-12-31 |
Vishal Sikka
BRD | Director/Board Member | 57 | 22-07-17 |
Wendy Becker
BRD | Director/Board Member | 58 | 23-09-30 |
Charles Bancroft
BRD | Director/Board Member | 65 | 20-04-30 |
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Director/Board Member | 67 | 22-08-31 | |
Jesse Goodman
BRD | Director/Board Member | 72 | 15-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 4,400,765,312 | 4,052,240,131 ( 92.08 %) | 255,885,366 ( 5.815 %) | 92.08 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
127,054,524 | 75.00% | 3,328,359,698 $ | |
HALEON PLC 4.17% | 385,320,110 | 4.17% | 1,615,523,919 $ |
VIR BIOTECHNOLOGY, INC. 6.33% | 8,550,954 | 6.33% | 96,112,723 $ |
GLAXOSMITHKLINE S.A.E 91.20% | 76,161,378 | 91.20% | 94,992,279 $ |
LYELL IMMUNOPHARMA, INC. 12.01% | 30,253,189 | 12.01% | 88,339,312 $ |
263,029,794 | 82.59% | 81,457,697 $ | |
HALEON PAKISTAN LIMITED 85.79% | 100,423,259 | 85.79% | 76,469,299 $ |
WAVE LIFE SCIENCES LTD. 11.75% | 13,983,761 | 11.75% | 67,261,890 $ |
CUREVAC N.V. 7.41% | 16,591,937 | 7.41% | 56,744,425 $ |
DONG-A ST CO., LTD. 8.06% | 707,859 | 8.06% | 39,815,738 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
GlaxoSmithKline Capital Plc
|
Finance/Rental/Leasing
|
GlaxoSmithKline Biologicals NV
GlaxoSmithKline Biologicals NV BiotechnologyHealth Technology GlaxoSmithKline Biologicals SA manufactures vaccines for diseases such as hepatitis, influenza, rubella, and typhoid fever. Its activities include overall strategy, research and development, clinical trials, regulatory matters, production, quality control, marketing, and distribution. The company has partnership with WHO and UNICEF. GlaxoSmithKline Biologicals was founded in 1945 and is headquartered in Rixensart, Belgium. |
Biotechnology
|
Eskaylab Ltd.
Eskaylab Ltd. Miscellaneous Commercial ServicesCommercial Services Founded in 1908, Eskaylab Ltd. is a testing British laboratory company that operates in Middlesex, UK. |
Miscellaneous Commercial Services
|
Horlicks Ltd.
Horlicks Ltd. Beverages: AlcoholicConsumer Non-Durables Horlicks Ltd. manufactures and distributes infant food products. The products it offers are Horlicks traditional, light and light chocolate. The company was founded on December 11, 1925 and is headquartered in Brentford, the United Kingdom. |
Beverages: Alcoholic
|
Novartis Consumer Health SA
Novartis Consumer Health SA Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Novartis Consumer Health SA is a private company based in Basel, Switzerland. |
Pharmaceuticals: Major
|
Glaxo Group Ltd.
Glaxo Group Ltd. Pharmaceuticals: MajorHealth Technology Founded in 1935, Glaxo Group Ltd. is a subsidiary of GSK Plc. The private company is based in Middlesex, UK. At GSK, we unite science, technology and talent to get ahead of disease together. |
Pharmaceuticals: Major
|
GlaxoSmithKline Finance Plc
|
Finance/Rental/Leasing
|
Setfirst Ltd.
Setfirst Ltd. Financial ConglomeratesFinance Part of GSK Plc, Setfirst Ltd. functions as an investment holding British company. The private company is based in Middlesex, UK. |
Financial Conglomerates
|
GlaxoSmithKline GmbH & Co. KG
GlaxoSmithKline GmbH & Co. KG Pharmaceuticals: MajorHealth Technology Part of GSK Plc, GlaxoSmithKline GmbH & Co. KG is a German pharmaceutical company. The private company is based in Munich, Germany. The CEOs of the company are Jean-Bernard Siméon, Adrian Bauer. |
Pharmaceuticals: Major
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.82% | 88.25B | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B |
- Stock
- Equities
- Stock GSK plc - London S.E.
- Company GSK plc